Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749630 | 0.92 | HPGDS (0.39) | HPGDSCTSLCTSBCTSSCTSK | |
| SCHEMBL6751642 | 0.91 | CTSL (0.45) | HPGDSCTSLCTSBCTSSCTSK | |
| SCHEMBL6985444 | 0.91 | HPGDS (0.39) | HPGDSCTSLCTSBCTSSCTSK | |
| SCHEMBL6747703 | 0.91 | CTSL (0.40) | HPGDSCTSLCTSBCTSSCTSK | |
| SCHEMBL6752290 | 0.91 | CTSL (0.46) | HPGDSCTSLRAB9A | |
| SCHEMBL6751811 | 0.90 | CTSL (0.48) | CTSLCTSBCTSSCTSKRAB9A | |
| SCHEMBL6752292 | 0.88 | HPGDS (0.37) | HPGDSCTSLRAB9APYGL | |
| SCHEMBL6749652 | 0.88 | TRPV1 (0.44) | HPGDSCTSL | |
| SCHEMBL6752382 | 0.88 | HPGDS (0.47) | HPGDSCTSLCTSBCTSSCTSK | |
| SCHEMBL6749632 | 0.86 | KDM1A (0.37) | HPGDSCTSLCTSBCTSSCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | HPGDS 1248/4885CTSL 23/4885CTSB 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.